Agonists and Antagonists of Neuropsychiatric Lupus
Agonists and Antagonists of Neuropsychiatric Lupus
批准号:
8145623
负责人:
Keith B. Elkon
金额:
$33.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-15 至 2013-06-30
关键词:
AddressAdultAffectAgonistAntibodiesAntigen-Antibody ComplexAseptic MeningitisAttenuatedAutoantibodiesBindingBiological MarkersBrainBrain InjuriesCell DeathCellsCerebrospinal FluidChildhoodClinicalCollectionComplementComplement 1qCoupledDataDefectDiffuseDinoprostoneDiseaseEmployee StrikesFunctional disorderFundingFutureGoalsHealthImmunoglobulin GIndividualInflammationInflammatoryInterferon Type IIInterferonsIntravenous ImmunoglobulinsLinkLiquid substanceLupusMagnetic Resonance ImagingMolecularNeurocognitiveNeuropsychiatric Systemic Lupus ErythematosusNon-Steroidal Anti-Inflammatory AgentsNucleoproteinsPathogenesisPatientsPeripheral Blood Mononuclear CellPlayPopulationProcessProductionPropertyProteinsProteomicsPublicationsReceptor SignalingRelative (related person)RoleSerumSignal TransductionSpecificitySubgroupSystemic Lupus ErythematosusTestingTherapeutic UsesToll-like receptorsbrain cellcell injurycell typecentral nervous system injurycytokinefollow-upinhibitor/antagonistmonocytenervous system disorderneuropsychiatryreceptorresponsesialylationuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Agonists and Antagonists of Neuropsychiatric Lupus Project Summary Neuropsychiatric systemic lupus erythematosus (NPSLE) is a common and potentially lethal form of lupus. Two abnormalities have consistently been linked to NPSLE: the presence of autoantibodies and the presence of pro-inflammatory cytokines. However, the role of individual autoantibodies as well as specific cytokines remains controversial and the relationship between these two abnormalities is relatively unexplored. In our previously funded R21 proposal, we hypothesized that cell death coupled with the release of nucleoproteins resulted in the formation of immune complexes that stimulate Toll like receptors (TLRs) to produce high local concentrations of type 1 IFN (and perhaps other cytokines). In preliminary data, we have indeed observed that cerebrospinal fluid (CSF) from NPSLE patients have significantly higher interferon (IFN)-a inducing potential compared to controls and that, normalized for IgG concentrations, the IFN inducing activity was 800-fold higher than serum. The high IFN inducing activity of autoantibodies in CSF relative to serum was explained by the low concentration of certain protein inhibitors in CSF. In the current proposal, we will ask the following questions: 1) Does the IFN-a or other cytokine inducing activity of immune complexes correlate with autoantibody specificity, disease subsets or CNS injury in patients with NPSLE? Cytokine inducing capacity of serum and CSF from well characterized NPSLE patients will be compared between the 19 case definitions of NPSLE, between different autoantibody specificities as determined by a proteomic array and correlations determined with markers of brain cell injury. In the pediatric population, we will examine whether IFN-a inducing activity is associated with neurocognitive defects or MRI changes. 2) In the second Aim, we ask what are the mechanisms whereby two identified serum factors inhibit IFG activity? At least two serum factors have been identified that suppress IFN-a inducing activity by autoantibodies in CSF. We will identify the cell type and receptors that the inhibitors act on and then investigate the mechanism of inhibition. Relevance: Even when the most common (but least specific) subtypes of NPSLE are excluded, NPSLE occurs in about half of pediatric cases of SLE and a high proportion of cases with adult SLE. We have documented the potent inflammatory potential of autoantibodies in the CSF of NPSLE patients and have identified protein inhibitors. The ready availability of these inhibitors will allow us to consider therapeutic uses in the future. PUBLIC HEALTH RELEVANCE: Agonists and Antagonists of Neuropsychiatric Lupus Project Narrative The cause(s) of most cases of lupus affecting the brain are unknown, but there is good evidence to suggest that certain types of antibodies may play a role. We have documented that these antibodies in brain fluid can cause the production of certain inflammatory proteins. Here, we determine which types of neurological disease are associated with specific inflammatory proteins and we determine how certain protein inhibitors can be used to dampen the inflammation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
cGAMP as an immunotransmitter of the interferon response to UV light
-
批准号:10215860
-
项目类别:
-
资助金额:$42.71万
-
财政年份:2021
-
负责人:Keith B. Elkon
-
依托单位:
Mechanisms of end organ damage in novel polygenic lupus models
-
批准号:10007264
-
项目类别:
-
资助金额:$40.48万
-
财政年份:2019
-
负责人:Keith B. Elkon
-
依托单位:
Link between Retroelements, Ro and Interferon Biology in Lupus
-
批准号:9378686
-
项目类别:
-
资助金额:$23.23万
-
财政年份:2017
-
负责人:Keith B. Elkon
-
依托单位:
Mechanisms of Ultraviolet Inflammation in Lupus
-
批准号:8769410
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2014
-
负责人:Keith B. Elkon
-
依托单位:
Agonists and Antagonists of Neuropsychiatric Lupus
-
批准号:7696866
-
项目类别:
-
资助金额:$34.94万
-
财政年份:2009
-
负责人:Keith B. Elkon
-
依托单位:
Agonists and Antagonists of Neuropsychiatric Lupus
-
批准号:8278629
-
项目类别:
-
资助金额:$33.38万
-
财政年份:2009
-
负责人:Keith B. Elkon
-
依托单位:
Nucleoprotein Immune Complexes and Interferon in Diffuse Neuropsychiatric SLE
-
批准号:7393201
-
项目类别:
-
资助金额:$16.43万
-
财政年份:2007
-
负责人:Keith B. Elkon
-
依托单位:
Nucleoprotein Immune Complexes and Interferon in Diffuse Neuropsychiatric SLE
-
批准号:7238549
-
项目类别:
-
资助金额:$20.11万
-
财政年份:2007
-
负责人:Keith B. Elkon
-
依托单位:
Apoptotic Cells As Immunogens In SLE
-
批准号:6653251
-
项目类别:
-
资助金额:$21.31万
-
财政年份:2001
-
负责人:Keith B. Elkon
-
依托单位:
Apoptotic Cells as Immunogens in SLE
-
批准号:7103193
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2001
-
负责人:Keith B. Elkon
-
依托单位:
Apoptotic Cells as Immunogens in SLE
-
批准号:7270072
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2001
-
负责人:Keith B. Elkon
-
依托单位:
Apoptotic Cells As Immunogens In SLE
-
批准号:6494510
-
项目类别:
-
资助金额:$30.56万
-
财政年份:2001
-
负责人:Keith B. Elkon
-
依托单位:
Apoptotic Cells as Immunogens in SLE
-
批准号:7659635
-
项目类别:
-
资助金额:$29.39万
-
财政年份:2001
-
负责人:Keith B. Elkon
-
依托单位:
Apoptotic Cells as Immunogens in SLE
-
批准号:7472328
-
项目类别:
-
资助金额:$29.39万
-
财政年份:2001
-
负责人:Keith B. Elkon
-
依托单位:
Apoptotic Cells As Immunogens In SLE
-
批准号:6935270
-
项目类别:
-
资助金额:$23.93万
-
财政年份:2001
-
负责人:Keith B. Elkon
-
依托单位:
Apoptotic Cells As Immunogens In SLE
-
批准号:6776491
-
项目类别:
-
资助金额:$23.98万
-
财政年份:2001
-
负责人:Keith B. Elkon
-
依托单位:
Apoptotic Cells As Immunogens In SLE
-
批准号:6533061
-
项目类别:
-
资助金额:$26.39万
-
财政年份:2001
-
负责人:Keith B. Elkon
-
依托单位:
Apoptotic Cells as Immunogens in SLE
-
批准号:7896516
-
项目类别:
-
资助金额:$29.1万
-
财政年份:2001
-
负责人:Keith B. Elkon
-
依托单位:
GENETIC CELLULAR AND MOLECULAR STUDIES OF FAS IN SLE
-
批准号:6016895
-
项目类别:
-
资助金额:$23.88万
-
财政年份:1998
-
负责人:Keith B. Elkon
-
依托单位:
GENETIC CELLULAR AND MOLECULAR STUDIES OF FAS IN SLE
-
批准号:6375149
-
项目类别:
-
资助金额:$27.82万
-
财政年份:1998
-
负责人:Keith B. Elkon
-
依托单位:
海外基金